JP2021505676A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021505676A5 JP2021505676A5 JP2020550062A JP2020550062A JP2021505676A5 JP 2021505676 A5 JP2021505676 A5 JP 2021505676A5 JP 2020550062 A JP2020550062 A JP 2020550062A JP 2020550062 A JP2020550062 A JP 2020550062A JP 2021505676 A5 JP2021505676 A5 JP 2021505676A5
- Authority
- JP
- Japan
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024005578A JP2024041959A (ja) | 2017-12-11 | 2024-01-17 | 抗ｃｄ２２抗体－メイタンシンコンジュゲートおよびその使用方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762597160P | 2017-12-11 | 2017-12-11 | |
| US62/597,160 | 2017-12-11 | ||
| PCT/US2018/064879 WO2019118411A2 (en) | 2017-12-11 | 2018-12-11 | Anti-cd22 antibody-maytansine conjugates, combinations, and methods of use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024005578A Division JP2024041959A (ja) | 2017-12-11 | 2024-01-17 | 抗ｃｄ２２抗体－メイタンシンコンジュゲートおよびその使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021505676A JP2021505676A (ja) | 2021-02-18 |
| JP2021505676A5 true JP2021505676A5 (https=) | 2021-05-06 |
| JP7466455B2 JP7466455B2 (ja) | 2024-04-12 |
Family
ID=66819489
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020550062A Active JP7466455B2 (ja) | 2017-12-11 | 2018-12-11 | 抗ｃｄ２２抗体－メイタンシンコンジュゲートおよびその使用方法 |
| JP2024005578A Pending JP2024041959A (ja) | 2017-12-11 | 2024-01-17 | 抗ｃｄ２２抗体－メイタンシンコンジュゲートおよびその使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024005578A Pending JP2024041959A (ja) | 2017-12-11 | 2024-01-17 | 抗ｃｄ２２抗体－メイタンシンコンジュゲートおよびその使用方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20190201541A1 (https=) |
| EP (1) | EP3723763A4 (https=) |
| JP (2) | JP7466455B2 (https=) |
| KR (1) | KR20200117992A (https=) |
| CN (1) | CN111787923A (https=) |
| AU (1) | AU2018385599A1 (https=) |
| BR (1) | BR112020011445A2 (https=) |
| CA (1) | CA3082912A1 (https=) |
| EA (1) | EA202091161A1 (https=) |
| IL (1) | IL275190A (https=) |
| MX (1) | MX2020006010A (https=) |
| SG (1) | SG11202004579RA (https=) |
| WO (1) | WO2019118411A2 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3373937B1 (en) | 2015-11-09 | 2021-12-22 | R.P. Scherer Technologies, LLC | Anti-cd22 antibody-maytansine conjugates and methods of use thereof |
| KR20200117992A (ko) * | 2017-12-11 | 2020-10-14 | 트리페이스 리서치 앤드 디벨로프먼트 쓰리 코포레이션 | 항-cd22 항체-메이탄신 컨쥬게이트, 그것의 조합, 및 사용 방법 |
| EP4037673A4 (en) | 2019-10-04 | 2023-08-16 | R.P. Scherer Technologies, LLC | ANTI-CD25 ANTIBODY-MAYTANSINE CONJUGATES AND METHODS OF USE THEREOF |
| EP4223775A4 (en) * | 2020-09-29 | 2025-07-30 | Kunming Sinoway Natural Pharmaceuticals Co Ltd | HUMANIZED RECOMBINANT ANTI-CD22 IMMUNOTOXIN AND ITS APPLICATION |
| US12187810B2 (en) | 2020-11-20 | 2025-01-07 | R.P. Scherer Technologies, Llc | Glycoside dual-cleavage linkers for antibody-drug conjugates |
| AU2022230398A1 (en) * | 2021-03-03 | 2023-08-31 | R.P. Scherer Technologies, Llc | Branched linkers for antibody-drug conjugates and methods of use thereof |
| US20250121090A1 (en) * | 2021-07-30 | 2025-04-17 | R.P. Scherer Technologies, Llc | Antibody-Drug Conjugates and Methods of Use Thereof |
| KR20240083175A (ko) * | 2021-08-25 | 2024-06-11 | 알.피.쉐러 테크놀러지즈 엘엘씨 | 항체-약물-접합체를 사용하는 방법 |
| TW202408585A (zh) * | 2022-05-13 | 2024-03-01 | 美商艾克塞里克斯公司 | 5t4抗體-藥物結合物及其用途 |
| WO2025019780A1 (en) * | 2023-07-20 | 2025-01-23 | Exelixis, Inc. | Activatable tyrosine-protein kinase membrane receptor (ror) antibody-drug conjugates and uses thereof |
| AU2024292307A1 (en) * | 2023-07-20 | 2026-01-29 | Exelixis, Inc. | Tyrosine-protein kinase membrane receptor 1 (ror1) antibody-drug conjugates and uses thereof |
| WO2025019776A2 (en) * | 2023-07-20 | 2025-01-23 | Exelixis, Inc. | Interleukin-13 receptor subunit alpha-2 antibody-drug conjugates and uses thereof |
| TW202527984A (zh) * | 2023-11-15 | 2025-07-16 | 美商艾克塞里克斯公司 | 5t4抗體藥物結合物及其使用之方法 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6306393B1 (en) * | 1997-03-24 | 2001-10-23 | Immunomedics, Inc. | Immunotherapy of B-cell malignancies using anti-CD22 antibodies |
| US7097840B2 (en) * | 2000-03-16 | 2006-08-29 | Genentech, Inc. | Methods of treatment using anti-ErbB antibody-maytansinoid conjugates |
| NZ579482A (en) * | 2004-06-01 | 2011-02-25 | Genentech Inc | Antibody drug conjugates and methods |
| JP2009532336A (ja) * | 2006-03-06 | 2009-09-10 | メディミューン，エルエルシー | ヒト化抗ｃｄ２２抗体、並びに腫瘍、移植及び自己免疫疾患の治療におけるこれらの使用 |
| WO2010096394A2 (en) * | 2009-02-17 | 2010-08-26 | Redwood Biosciences, Inc. | Aldehyde-tagged protein-based drug carriers and methods of use |
| CN107753954A (zh) * | 2012-12-13 | 2018-03-06 | 免疫医疗公司 | 功效改进且毒性降低的抗体与sn‑38的免疫缀合物的剂量 |
| CN105722859B (zh) * | 2013-07-25 | 2021-05-07 | 西托姆克斯治疗公司 | 多特异性抗体、多特异性可活化抗体及其使用方法 |
| CN115504924A (zh) * | 2013-11-27 | 2022-12-23 | 雷德伍德生物科技股份有限公司 | 肼基-吡咯并化合物及用于生成缀合物的方法 |
| JP6980980B2 (ja) * | 2015-06-25 | 2021-12-15 | イミューノメディクス、インコーポレイテッドImmunomedics, Inc. | 抗ｈｌａ‐ｄｒまたは抗ｔｒｏｐ‐２抗体と微小管阻害剤、ｐａｒｐ阻害剤、ブルトンキナーゼ阻害剤またはホスホイノシチド３‐キナーゼ阻害剤との併用は癌の治療効果を有意に改善する |
| EP3373937B1 (en) * | 2015-11-09 | 2021-12-22 | R.P. Scherer Technologies, LLC | Anti-cd22 antibody-maytansine conjugates and methods of use thereof |
| KR20200117992A (ko) * | 2017-12-11 | 2020-10-14 | 트리페이스 리서치 앤드 디벨로프먼트 쓰리 코포레이션 | 항-cd22 항체-메이탄신 컨쥬게이트, 그것의 조합, 및 사용 방법 |
-
2018
- 2018-12-11 KR KR1020207019323A patent/KR20200117992A/ko not_active Ceased
- 2018-12-11 US US16/216,233 patent/US20190201541A1/en not_active Abandoned
- 2018-12-11 WO PCT/US2018/064879 patent/WO2019118411A2/en not_active Ceased
- 2018-12-11 EP EP18888720.2A patent/EP3723763A4/en not_active Withdrawn
- 2018-12-11 CA CA3082912A patent/CA3082912A1/en active Pending
- 2018-12-11 CN CN201880079401.7A patent/CN111787923A/zh active Pending
- 2018-12-11 SG SG11202004579RA patent/SG11202004579RA/en unknown
- 2018-12-11 AU AU2018385599A patent/AU2018385599A1/en not_active Abandoned
- 2018-12-11 JP JP2020550062A patent/JP7466455B2/ja active Active
- 2018-12-11 EA EA202091161A patent/EA202091161A1/ru unknown
- 2018-12-11 MX MX2020006010A patent/MX2020006010A/es unknown
- 2018-12-11 BR BR112020011445-6A patent/BR112020011445A2/pt not_active Application Discontinuation
-
2020
- 2020-06-07 IL IL275190A patent/IL275190A/en unknown
-
2024
- 2024-01-17 JP JP2024005578A patent/JP2024041959A/ja active Pending